Toru Kondo

Soro, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Carboxy terminal of ECRG4 is a potential initiator for amyloid pathology in Alzheimer's disease through interacting with APP intracellular domain.

Carboxy terminal of ECRG4 is a potential initiator for amyloid pathology in Alzheimer's disease through interacting with APP intracellular domain.

Journal: Journal of Alzheimer's disease : JAD

Published: June 30, 2026

Plasma ECRG4 as a novel diagnostic marker for Alzheimer's disease associated with oligodendrocyte dysfunction.

Plasma ECRG4 as a novel diagnostic marker for Alzheimer's disease associated with oligodendrocyte dysfunction.

Journal: American journal of translational research

Published: February 19, 2026

Neuronal Differentiation of GBM-Initiating Cells Combined with Elimination of Undifferentiated Cells Preserves Motor Function.

Neuronal Differentiation of GBM-Initiating Cells Combined with Elimination of Undifferentiated Cells Preserves Motor Function.

Journal: Cells

Published: February 13, 2026

Fragment of esophageal cancer-related gene-4 induces lysosome-dependent cell death via cathepsin secretion in astrocytes.

Fragment of esophageal cancer-related gene-4 induces lysosome-dependent cell death via cathepsin secretion in astrocytes.

Journal: Tissue & cell

Published: November 17, 2025

MAP17 Enhances Chemoresistance and Tumorigenicity of Glioblastoma-Initiating Cells via the Canonical NF-кB Pathway.

MAP17 Enhances Chemoresistance and Tumorigenicity of Glioblastoma-Initiating Cells via the Canonical NF-кB Pathway.

Journal: Cancer science

Published: October 15, 2025

Corrigendum to "Eva1 deficiency prevents obesity-induced metabolic disorders by reducing visceral adipose dysfunction" [Metabolism 168 (2025) 156235].

Corrigendum to "Eva1 deficiency prevents obesity-induced metabolic disorders by reducing visceral adipose dysfunction" [Metabolism 168 (2025) 156235].

Journal: Metabolism: clinical and experimental

Published: May 29, 2025

Eva1 deficiency prevents obesity-induced metabolic disorders by reducing visceral adipose dysfunction.

Eva1 deficiency prevents obesity-induced metabolic disorders by reducing visceral adipose dysfunction.

Journal: Metabolism: clinical and experimental

Published: January 17, 2025

EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells.

EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells.

Journal: Neuro-oncology

Published: October 29, 2024

Novel strategy to target glioblastoma-initiating cells using a braintropic adeno-associated virus carrying a miR-dependent genome-editing system.

Novel strategy to target glioblastoma-initiating cells using a braintropic adeno-associated virus carrying a miR-dependent genome-editing system.

Journal: British journal of cancer

Published: July 22, 2024

Combination of blockade of endothelin signalling and compensation of IGF1 expression protects the retina from degeneration.

Combination of blockade of endothelin signalling and compensation of IGF1 expression protects the retina from degeneration.

Journal: Cellular and molecular life sciences : CMLS

Published: July 22, 2023

Selective vulnerability of human-induced pluripotent stem cells to dihydroorotate dehydrogenase inhibition during mesenchymal stem/stromal cell purification.

Selective vulnerability of human-induced pluripotent stem cells to dihydroorotate dehydrogenase inhibition during mesenchymal stem/stromal cell purification.

Journal: Frontiers in cell and developmental biology

Published: November 04, 2022

Cancer cell heterogeneity and plasticity: From molecular understanding to therapeutic targeting.

Cancer cell heterogeneity and plasticity: From molecular understanding to therapeutic targeting.

Journal: Seminars in cancer biology

Published: October 09, 2021

Showing 1-12 of 38

Last Updated: 09/26/2026